The clinical AI wave in dentistry isn't coming — it's here. On February 24, 2026, Pearl announced that DECA Dental Group, a Dallas-based DSO operating across nine states, had selected Pearl as its exclusive dental AI partner and was rolling out the platform to its entire network of supported clinics. That's a big signal for the industry.
If you're a practice owner, office manager, or DSO operator who's been watching dental AI from the sidelines, this is the moment to get educated. This review covers Pearl's core product — Second Opinion® — in plain terms: what it is, what it claims to do, what the FDA has cleared, how it integrates, and who should (and shouldn't) be considering it right now.
1. What Is Pearl AI?
Pearl (hellopearl.com) is a Los Angeles-based dental AI company founded in 2019. Their flagship product is Second Opinion®, an AI-powered radiologic analysis tool that reviews dental X-rays in real time and flags potential pathologies for clinician review. The company markets itself as "the global leader in dental AI solutions" and reports more than 50,000 clinicians using its platform.
The core premise is simple: clinicians are human, and subtle findings — early interproximal caries, early bone loss, calculus, periapical lesions — can be easy to miss in a fast-paced clinical day. Pearl's AI acts as a second set of eyes on every radiograph, surfacing potential findings that might otherwise be overlooked or not communicated clearly to patients.
Pearl also offers Practice Intelligence, an enterprise analytics layer built for DSOs and multi-location groups. It provides aggregate diagnostic data across locations, helping operators standardize care quality and identify performance trends.
2. Key Features of Second Opinion®
Pearl's Second Opinion® product analyzes dental radiographs and flags a range of findings. Based on publicly available information from Pearl and clinical press coverage, the platform currently detects:
- Interproximal and occlusal caries (cavities at various stages)
- Periapical radiolucencies (potential infection/abscess indicators)
- Bone loss (a key indicator for periodontal disease staging)
- Calculus deposits
- Crown and restoration anomalies (overhangs, open margins, secondary decay)
- Other radiographic pathologies flagged via its AI detection models
The platform overlays color-coded annotations directly on X-ray images, making findings visually intuitive for both the clinician and the patient. Pearl positions this patient-facing visualization as a key driver of case acceptance — the idea being that patients are more likely to approve treatment when they can see what the dentist is describing.
A notable differentiator Pearl emphasizes: it writes AI findings directly into practice management software — not just as a side panel or separate screen, but as entries in the clinical record itself. This keeps the workflow continuous rather than requiring clinicians to toggle between platforms.
Note on the 37% statistic: This figure comes from Pearl's own marketing. Independent peer-reviewed validation data is limited — as is the case with most dental AI platforms. Treat vendor-supplied accuracy claims as directional, not definitive, and ask for supporting study methodology when evaluating.
3. FDA Clearance: What's Actually Cleared?
FDA clearance is a meaningful differentiator in clinical AI — it means the device has been reviewed under the 510(k) pathway and deemed substantially equivalent to a predicate device for a specific indicated use. It does not mean the FDA has independently validated accuracy claims in real-world settings.
As of early 2026, Pearl holds multiple FDA clearances:
- Bitewing and periapical X-rays — Pearl's Second Opinion® has been FDA-cleared for automated detection of dental pathologies on 2D bitewing and periapical radiographs.
- Panoramic X-rays — In December 2025, Pearl announced FDA clearance for automated pathology detection on panoramic radiographs, a diagnostically complex format due to anatomical overlap and distortion.
- CBCT / 3D imaging — In May 2025, Pearl announced it became the first dental AI company to receive FDA clearance for both 2D and 3D (CBCT) imaging. The 3D clearance followed bench performance testing showing high segmentation accuracy across targeted anatomical structures.
This multi-modality FDA clearance stack is notable. Many dental AI competitors have cleared 2D only. Pearl's panoramic and 3D clearances give it broader clinical coverage — particularly relevant for practices that use CBCT for implant planning or complex cases.
4. Recent Traction: The DECA Dental Deployment
On February 24, 2026, Pearl and DECA Dental Group announced a full enterprise deployment following a successful pilot study. DECA — a Dallas-based DSO with clinics spanning nine states — selected Pearl as its exclusive dental AI partner.
According to the press release, DECA's decision followed a pilot in which Pearl generated measurable improvements in case acceptance by helping clinicians present radiographic findings more clearly through AI-visualized X-rays. Pearl reportedly generated a significant early return on investment during the pilot, which was the basis for the enterprise-wide rollout decision.
"As a clinician-led organization, our responsibility is to listen to our doctors' needs and ensure they have the best tools on the market to unlock confident, consistent diagnosis." — DECA Dental Group leadership (per Pearl press release, Feb. 24, 2026)
DECA joins a growing list of DSOs that have publicly adopted dental AI platforms in recent months, including Heartland Dental, Aspen Dental, and Great Expressions Dental Centers, according to Becker's Dental Review reporting. See: the DSO AI arms race and what it means for independent practices →
The pattern is becoming clear: large DSOs are standardizing diagnostic AI across their networks, partly for clinical consistency and partly for the documentable case acceptance improvements it produces. Independent practices that haven't evaluated these tools are operating at an increasing disadvantage in both diagnostic thoroughness and patient communication.
5. How Pearl Integrates
Integration friction is one of the biggest barriers to clinical AI adoption — if the tool requires clinicians to change their workflow significantly, adoption stalls regardless of how good the technology is. Pearl has positioned integration as a core competitive advantage.
Pearl claims compatibility with a broad range of existing dental platforms:
- X-ray software / imaging platforms: Pearl integrates with major dental imaging systems. The AI analysis layer appears within the existing imaging viewer rather than requiring a separate application.
- Practice management software (PMS): As noted, Pearl writes findings directly into the PMS clinical record. This is a claimed differentiator — most competitors overlay findings on images only, without creating PMS entries.
- Patterson Dental / Eaglesoft: Pearl has a documented partnership with Patterson Dental. As of early 2026, Patterson was actively promoting Pearl integration for Eaglesoft users, including a 60-day free trial offer for new customers using Eaglesoft Advanced Imaging.
For DSO environments — where standardization across locations is critical — the PMS write-back capability matters significantly. It allows enterprise reporting on AI findings across the entire network, which is what products like Pearl's Practice Intelligence are built on.
If you're evaluating Pearl for a specific imaging or PMS setup, verify direct integration before signing. Ask Pearl explicitly whether your imaging software and PMS version are on the supported list — and ask about the integration path for any platforms that require middleware.
6. Pricing
Pearl does not publish pricing publicly. Like most enterprise dental software, pricing is quote-based and likely varies by practice size, number of locations, and contract term.
The Patterson Dental partnership suggests that some entry points exist through distribution channels — the 60-day free trial offer for Eaglesoft users (valid through February 28, 2026 per Patterson's site) is one example of a structured market access path.
For independent practices, expect a demo-first sales process. For DSOs, Pearl likely has dedicated enterprise pricing with volume tiers. If you want a benchmark before entering that conversation, the dental AI platform comparison guide → covers what peer products typically charge.
Bottom line on pricing: Contact Pearl for a quote. Come into that conversation knowing your imaging volume, PMS platform, and number of operatories — those are the variables most likely to affect your price.
7. Who Pearl Is Best For
Strong Fit
- Practices wanting to improve case acceptance through better patient visualization
- Clinicians who take regular bitewing and periapical X-rays and want a diagnostic safety net
- DSOs standardizing diagnostic quality and documentation across multiple locations
- Practices using CBCT who want AI-assisted 3D analysis (post-clearance)
- Operations using Eaglesoft or other Pearl-integrated PMS platforms
- Groups that want enterprise-wide diagnostic performance data via Practice Intelligence
Weaker Fit
- Practices that don't take X-rays routinely or have low radiographic volume
- Solo practices with tight technology budgets and no clear ROI case
- Teams not prepared to explain AI to patients who may be skeptical or anxious
- Practices on legacy PMS/imaging software not supported by Pearl's integration stack
- Owners who want to pilot before committing — ask specifically about trial terms
8. The HIPAA and Clinical Data Question
Any time you're sending patient radiographic data to a third-party AI platform, you are creating a HIPAA Business Associate relationship. That's not a reason to avoid clinical AI — it's a reason to evaluate it carefully.
AI diagnostics should augment clinical judgment, not replace it. The clinician remains responsible for the diagnosis. Understand your liability exposure — and your patients' consent expectations — before deploying any clinical AI tool.
Before signing with Pearl (or any clinical AI vendor), work through these questions:
HIPAA & Data Due Diligence Checklist
- Is a Business Associate Agreement (BAA) included in the contract?
- Where is patient imaging data stored, and in what jurisdiction?
- Is patient data used to train or improve the AI model? If so, what's the opt-out process?
- What happens to stored data if you cancel the contract?
- Does the platform support data deletion requests (for HIPAA or state privacy law compliance)?
- What encryption standards apply to data in transit and at rest?
- Has Pearl completed a SOC 2 or equivalent audit? Can they provide the report?
- What is the breach notification timeline and process?
These aren't gotcha questions — reputable vendors expect them and have documented answers. If a vendor can't answer these fluently, that's a red flag. For a deeper treatment of this topic, see our HIPAA and clinical AI compliance guide →
On the patient communication side: some patients will be curious about AI on their X-rays; others may be uncomfortable. Having a brief, clear explanation ready — "this AI flags potential findings for my review, and I make all clinical decisions" — goes a long way toward maintaining trust.
9. Bottom Line
Pearl AI is the most credentialed dental diagnostic AI platform on the market right now. Multiple FDA clearances across 2D, panoramic, and 3D modalities; deep DSO traction including the February 2026 DECA deployment; 50,000+ clinician users; and a differentiated PMS write-back architecture that sets it apart from competitors who only annotate images.
The DECA deployment is meaningful news — not as marketing, but as market signal. When a DSO of that size selects an exclusive clinical AI partner and rolls it out enterprise-wide after a pilot that demonstrated measurable case acceptance improvement, it validates the product category and Pearl's position within it.
For independent practices, the value proposition is straightforward: if you're leaving treatable disease undiagnosed — even occasionally — or struggling to help patients understand why they need treatment, Pearl addresses both problems simultaneously. Whether the ROI justifies the price at your volume is a math problem worth running. The Dental AI Starter Kit includes a worksheet to help you do exactly that.
For DSOs evaluating platform standardization, Pearl's Practice Intelligence layer and PMS integration architecture make it purpose-built for enterprise deployment in a way that solo-practice tools are not. See how Pearl compares to other dental AI platforms →